The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.
Novo Nordisk scientists have synthesised an insulin molecule that specifically targets glucose in blood, instead of other sugars like fructose, to aid treatment of all types of diabetes.
Doctors Without Borders says new class of drugs & insulin devices could be leading to ‘exorbitant corporate profiteering’. Study published in Journal of the American Medical Association.
Icodec has been touted as a therapy that could eliminate the need for daily or mealtime insulin injections for people with severe diabetes. It has not been approved by any country so far.
Danish pharmaceutical giant Novo Nordisk has said it is set to apply for regulatory approval of its once-a-week insulin drug, Icodec. Results of Phase-3 clinical trial shown 'promising results'.
UK patients may soon be covered for the device, which measures blood glucose, computes amount of insulin needed and then pumps that exact amount into bloodstream.
If extremely heavy rainfall can cause such damage without a rare event like a cloudburst, it should leave the system working toward India’s disaster preparedness thinking.
One such website has drawn particular scrutiny for spreading fake stories that have upset not only the Indian but also foreign defence firms by falsely attributing misinformation.
Standing up to America is usually not a personal risk for a leader in India. Any suggestions of foreign pressure unites India behind who they see as leading them in that fight.
COMMENTS